Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients - PubMed (original) (raw)

Clinical Trial

. 2012 Jul 1;131(1):140-9.

doi: 10.1002/ijc.26365. Epub 2011 Sep 14.

Heinrich Griesemann, Stefan Stevanović, Susan Feyerabend, Reinhild Klein, Sebastian Attig, Jörg Hennenlotter, Dorothee Wernet, Dmitri V Kuprash, Alexei Y Sazykin, Steve Pascolo, Arnulf Stenzl, Cécile Gouttefangeas, Hans-Georg Rammensee

Affiliations

Clinical Trial

Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients

Melanie Widenmeyer et al. Int J Cancer. 2012.

Abstract

CD4(+) T cells have been shown to be crucial for the induction and maintenance of cytotoxic T cell responses and to be also capable of mediating direct tumor rejection. Therefore, the anticancer therapeutic efficacy of peptide-based vaccines may be improved by addition of HLA class II epitopes to stimulate T helper cells. Survivin is an apoptosis inhibiting protein frequently overexpressed in tumors. Here we describe the first immunological evaluation of a survivin-derived CD4(+) T cell epitope in a multipeptide immunotherapy trial for prostate carcinoma patients. The survivin peptide is promiscuously presented by several human HLA-DRB1 molecules and, most importantly, is naturally processed by dendritic cells. In vaccinated patients, it was able to induce frequent, robust and multifunctional CD4(+) T cell responses, as monitored by IFN-γ ELISPOT and intracellular cytokine staining. Thus, this HLA-DR restricted epitope is broadly immunogenic and should be valuable for stimulating T helper cells in patients suffering from a wide range of tumors.

Copyright © 2011 UICC.

PubMed Disclaimer

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources